VPL vs XBI
Vanguard FTSE Pacific ETF vs SPDR S&P Biotech ETF
- • VPL has the lower expense ratio at 0.07% vs 0.35% for XBI.
- • VPL pays a higher dividend yield (2.99%).
Side-by-side metrics
| Metric | VPL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.07% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.99% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $13.07B | $8.30B |
YTD return | 24.54% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.06 | 1.09 |
P/E ratio | 19.58 | — |
Last price | $111.07 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VPL top holdings
| 005930.KS | Samsung Electronics Co Ltd | 5.06% |
| 000660.KS | SK Hynix Inc | 2.82% |
| 7203.T | Toyota Motor Corp | 2.03% |
| CBA.AX | Commonwealth Bank of Australia | 1.80% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 1.71% |
| BHP.AX | BHP Group Ltd | 1.63% |
| 6501.T | Hitachi Ltd | 1.17% |
| 6758.T | Sony Group Corp | 1.15% |
| 8316.T | Sumitomo Mitsui Financial Group Inc | 1.11% |
| 1299.HK | AIA Group Ltd | 1.07% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VPL
VPL (Vanguard FTSE Pacific ETF) is Developed Pacific-region equities. Managed by Vanguard, the fund carries $13.1B in assets under management, an expense ratio of 0.07%, a dividend yield of 2.99%. Its largest holding is Samsung Electronics Co Ltd (005930.KS), which represents 5.1% of the portfolio. Real Estate is the fund's largest sector exposure at 4.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.